These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
273 related articles for article (PubMed ID: 30089916)
1. The stem cell-associated gene expression signature allows risk stratification in pediatric acute myeloid leukemia. Duployez N; Marceau-Renaut A; Villenet C; Petit A; Rousseau A; Ng SWK; Paquet A; Gonzales F; Barthélémy A; Leprêtre F; Pottier N; Nelken B; Michel G; Baruchel A; Bertrand Y; Leverger G; Lapillonne H; Figeac M; Dick JE; Wang JCY; Preudhomme C; Cheok M Leukemia; 2019 Feb; 33(2):348-357. PubMed ID: 30089916 [TBL] [Abstract][Full Text] [Related]
2. A 17-gene stemness score for rapid determination of risk in acute leukaemia. Ng SW; Mitchell A; Kennedy JA; Chen WC; McLeod J; Ibrahimova N; Arruda A; Popescu A; Gupta V; Schimmer AD; Schuh AC; Yee KW; Bullinger L; Herold T; Görlich D; Büchner T; Hiddemann W; Berdel WE; Wörmann B; Cheok M; Preudhomme C; Dombret H; Metzeler K; Buske C; Löwenberg B; Valk PJ; Zandstra PW; Minden MD; Dick JE; Wang JC Nature; 2016 Dec; 540(7633):433-437. PubMed ID: 27926740 [TBL] [Abstract][Full Text] [Related]
3. High NCALD expression predicts poor prognosis of cytogenetic normal acute myeloid leukemia. Song Y; Zhang W; He X; Liu X; Yang P; Wang J; Hu K; Liu W; Zhang X; Jing H; Yuan X J Transl Med; 2019 May; 17(1):166. PubMed ID: 31109331 [TBL] [Abstract][Full Text] [Related]
4. Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia. Gentles AJ; Plevritis SK; Majeti R; Alizadeh AA JAMA; 2010 Dec; 304(24):2706-15. PubMed ID: 21177505 [TBL] [Abstract][Full Text] [Related]
6. Reduced protocadherin17 expression in leukemia stem cells: the clinical and biological effect in acute myeloid leukemia. Xu ZJ; Ma JC; Zhou JD; Wen XM; Yao DM; Zhang W; Ji RB; Wu DH; Tang LJ; Deng ZQ; Qian J; Lin J J Transl Med; 2019 Mar; 17(1):102. PubMed ID: 30922328 [TBL] [Abstract][Full Text] [Related]
7. A clinical laboratory-developed LSC17 stemness score assay for rapid risk assessment of patients with acute myeloid leukemia. Ng SWK; Murphy T; King I; Zhang T; Mah M; Lu Z; Stickle N; Ibrahimova N; Arruda A; Mitchell A; Mai M; He R; Madala BS; Viswanatha DS; Dick JE; Chan S; Virtanen C; Minden MD; Mercer T; Stockley T; Wang JCY Blood Adv; 2022 Feb; 6(3):1064-1073. PubMed ID: 34872104 [TBL] [Abstract][Full Text] [Related]
8. Integrated stem cell signature and cytomolecular risk determination in pediatric acute myeloid leukemia. Huang BJ; Smith JL; Farrar JE; Wang YC; Umeda M; Ries RE; Leonti AR; Crowgey E; Furlan SN; Tarlock K; Armendariz M; Liu Y; Shaw TI; Wei L; Gerbing RB; Cooper TM; Gamis AS; Aplenc R; Kolb EA; Rubnitz J; Ma J; Klco JM; Ma X; Alonzo TA; Triche T; Meshinchi S Nat Commun; 2022 Sep; 13(1):5487. PubMed ID: 36123353 [TBL] [Abstract][Full Text] [Related]
9. Development and validation of a promising 5-gene prognostic model for pediatric acute myeloid leukemia. Tao Y; Wei L; Shiba N; Tomizawa D; Hayashi Y; Ogawa S; Chen L; You H Mol Biomed; 2024 Jan; 5(1):1. PubMed ID: 38163849 [TBL] [Abstract][Full Text] [Related]
10. High DOCK1 expression identifies a distinct prognostic subgroup of pediatric acute myeloid leukemia: Results of the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05 trial. Yoshitomi M; Tsujimoto SI; Ikeda J; Kawai T; Ohki K; Hara Y; Yamato G; Tanoshima R; Tomizawa D; Shimada A; Horibe K; Adachi S; Taga T; Tawa A; Hayashi Y; Ito S; Shiba N Pediatr Blood Cancer; 2024 Sep; 71(9):e31151. PubMed ID: 38953149 [TBL] [Abstract][Full Text] [Related]
11. A Novel 85-Gene Expression Signature Predicts Unfavorable Prognosis in Acute Myeloid Leukemia. Lai Y; Sheng L; Wang J; Zhou M; OuYang G Technol Cancer Res Treat; 2021; 20():15330338211004933. PubMed ID: 33784904 [TBL] [Abstract][Full Text] [Related]
12. The lincRNA HOTAIRM1, located in the HOXA genomic region, is expressed in acute myeloid leukemia, impacts prognosis in patients in the intermediate-risk cytogenetic category, and is associated with a distinctive microRNA signature. Díaz-Beyá M; Brunet S; Nomdedéu J; Pratcorona M; Cordeiro A; Gallardo D; Escoda L; Tormo M; Heras I; Ribera JM; Duarte R; de Llano MP; Bargay J; Sampol A; Nomdedeu M; Risueño RM; Hoyos M; Sierra J; Monzo M; Navarro A; Esteve J; Oncotarget; 2015 Oct; 6(31):31613-27. PubMed ID: 26436590 [TBL] [Abstract][Full Text] [Related]
13. LSC17 score complements genetics and measurable residual disease in acute myeloid leukemia: an ALFA study. Vasseur L; Fenwarth L; Lambert J; de Botton S; Figeac M; Villenet C; Heiblig M; Dumas PY; Récher C; Berthon C; Lemasle E; Lebon D; Lambert J; Terré C; Celli-Lebras K; Dombret H; Preudhomme C; Cheok M; Itzykson R; Duployez N Blood Adv; 2023 Aug; 7(15):4024-4034. PubMed ID: 37205853 [TBL] [Abstract][Full Text] [Related]
14. Distinct prognostic values of Annexin family members expression in acute myeloid leukemia. Niu Y; Yang X; Chen Y; Jin X; Xie Y; Tang Y; Li L; Liu S; Guo Y; Li X; Duan L; Wang H Clin Transl Oncol; 2019 Sep; 21(9):1186-1196. PubMed ID: 30694461 [TBL] [Abstract][Full Text] [Related]
15. A 4-microRNA signature for survival prognosis in pediatric and adolescent acute myeloid leukemia. Zhu R; Lin W; Zhao W; Fan F; Tang L; Hu Y J Cell Biochem; 2019 Mar; 120(3):3958-3968. PubMed ID: 30242879 [TBL] [Abstract][Full Text] [Related]
16. High proportion of leukemic stem cells at diagnosis is correlated with unfavorable prognosis in childhood acute myeloid leukemia. Witte KE; Ahlers J; Schäfer I; André M; Kerst G; Scheel-Walter HG; Schwarze CP; Pfeiffer M; Lang P; Handgretinger R; Ebinger M Pediatr Hematol Oncol; 2011 Mar; 28(2):91-9. PubMed ID: 21214408 [TBL] [Abstract][Full Text] [Related]
17. The outcomes of relapsed acute myeloid leukemia in children: Results from the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05R study. Moritake H; Tanaka S; Miyamura T; Nakayama H; Shiba N; Shimada A; Terui K; Yuza Y; Koh K; Goto H; Kakuda H; Saito A; Hasegawa D; Iwamoto S; Taga T; Adachi S; Tomizawa D Pediatr Blood Cancer; 2021 Jan; 68(1):e28736. PubMed ID: 32991072 [TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of the EVI1 gene expression in patients with acute myeloid leukemia: a meta-analysis. Wu X; Wang H; Deng J; Zheng X; Ling Y; Gong Y Ann Hematol; 2019 Nov; 98(11):2485-2496. PubMed ID: 31482295 [TBL] [Abstract][Full Text] [Related]
19. Overexpression of CD200 and CD123 is a major influential factor in the clinical course of pediatric acute myeloid leukemia. Kandeel EZ; Madney Y; Eldin DN; Shafik NF Exp Mol Pathol; 2021 Feb; 118():104597. PubMed ID: 33358743 [TBL] [Abstract][Full Text] [Related]
20. A stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemia. Metzeler KH; Maharry K; Kohlschmidt J; Volinia S; Mrózek K; Becker H; Nicolet D; Whitman SP; Mendler JH; Schwind S; Eisfeld AK; Wu YZ; Powell BL; Carter TH; Wetzler M; Kolitz JE; Baer MR; Carroll AJ; Stone RM; Caligiuri MA; Marcucci G; Bloomfield CD Leukemia; 2013 Oct; 27(10):2023-31. PubMed ID: 23765227 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]